MARS: mutation-adjusted risk score for advanced systemic mastocytosis
1 Visningar
• 07/09/23
0
0
Bädda in
administrator
Prenumeranter
Andreas Reiter, MD, University Medical Centre, Mannheim, Germany, discusses how a mutation-adjusted risk score (MARS) may improve treatment stratification for advanced systemic mastocytosis (AdvSM). This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.
Visa mer
Facebook-kommentarer
SORT BY-
Toppkommentarer
-
Senaste kommentarerna